Table 4.
Risk factors for 28-day mortality among 36 patients infected by tigecycline non-susecptible K. pneumoniae bacteremia
| Survivors (n = 22), n (%) | Non-survivors (n = 14), n (%) | p | Adjustedp a | |
|---|---|---|---|---|
| Age (years, median, IQR) |
76.5, 69.3–84.3 |
71, 60.3–79 |
0.175 |
|
| Male sex |
17 (77.3) |
10 (71.4) |
0.988 |
|
| Underlying disease |
|
|
|
|
| Immunosuppressionb |
5 (22.7) |
4 (28.6) |
0.988 |
|
| Diabetes mellitus |
9 (40.9) |
9 (64.3) |
0.305 |
|
| Chronic obstructive lung disease |
2 (9.1) |
3 (21.4) |
0.574 |
|
| Hemodialysis |
5 (22.7) |
6 (42.9) |
0.364 |
|
| Malignancy |
7 (31.8) |
7 (50) |
0.458 |
|
| Liver cirrhosis |
2 ( 9.1) |
1 (7.1) |
1.000 |
|
| Cerebral vascular disease |
6 (27.3) |
4 (28.6) |
1.000 |
|
| Charlson comorbidity score (median, IQR) |
3, 2–5 |
4, 3–8.3 |
0.171 |
|
| Pitt bacteremia score (mean ± SD) |
3.3 ± 3.1 |
5.9 ± 3.7 |
0.037 |
0.847 |
| APACHE II score (mean ± SD) |
20.1 ± 0.6 |
27.6 ± 11.0 |
0.016 |
0.958 |
| Acquired after ICU >48 h |
3 (13.6) |
11 (78.6) |
<0.001 |
0.021 |
| Infection sources and clinical syndrome |
|
|
|
|
| Pneumonia |
3 (13.6) |
7 (50) |
0.047 |
0.569 |
| Intra-abdominal infection other than biliary-tract infection |
2 (9.1) |
3 (21.4) |
0.574 |
|
| Biliary-tract infection |
7 (31.8) |
0 (0) |
|
|
| Unknown primary focus |
8 (36.4) |
2 (14.3) |
0.289 |
|
| Presentation with septic shock |
9 (40.9) |
10 (71.4) |
0.147 |
|
| Appropriate antibiotic treatment |
12 (54.6) |
6 (42.9) |
0.733 |
|
| Ertapenem non-susceptibility |
6 (27.3) |
2 (14.3) |
0.628 |
|
| Tigecycline MIC >4 μg/mL |
10 (45.5) |
8 (57.1) |
0.733 |
|
| Tigecycline MIC >6 μg/mL |
4 (18.2) |
6 (42.9) |
0.220 |
|
| ESBL-producing strain | 10 (45.5) | 8 (57.1) | 0.733 |
IQR, interquartile range; ICU, intensive care unit; APACHE, Acute Physiology and Chronic Health Evaluation; SD, standard deviation.
aAll factors with p < 0.1 in univariate analyses were included in the exact logistic regression.
bImmunosuppression includes patients who underwent solid-organ transplantation, corticosteroid therapy, and immunosuppression therapy.